General Information of Drug (ID: DMU3VWA)

Drug Name
1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine Drug Info
Synonyms
CHEMBL101135; 5-methyl-1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione; AC1O54TL; 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine; 5-Methyl-1-(4-trityloxy-but-2-enyl)-1H-pyrimidine-2,4-dione; SCHEMBL19196301; BDBM50118490; 5-Methyl-1-[(2Z)-4-(trityloxy)but-2-enyl]pyrimidine-2,4(1H,3H)-dione
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
6477686
TTD Drug ID
DMU3VWA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug(s) Targeting Thymidine kinase 2 (Mt-TK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MT-1621 DMUNBMA Thymidine kinase 2 deficiency 5C55.1 Phase 3 [2]
1-[5-(triphenylmethoxy)pentyl]thymine DMFHBJM Discovery agent N.A. Investigative [1]
1-[6-(triphenylmethoxy)hexyl]thymine DM5NVHO Discovery agent N.A. Investigative [1]
Drug(s) Targeting Thymidine kinase 1 (TK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Penciclovir DMOUMDV Herpes simplex labialis 1F00.01 Approved [3]
DEOXYCYTIDINE DMYE5LJ Acute myeloid leukaemia 2A60 Approved [4]
TK-DLI DM26I8H Graft-versus-host disease 4B24 Preregistration [5]
FV-100 DMZARP1 Varicella zoster virus infection 1E91 Phase 3 [6]
Radiosensitizer gene therapy DMN1ZEU Pancreatic cancer 2C10 Phase 3 [7]
RP101 DMNIYSZ Infectious disease 1A00-CA43.1 Phase 2/3 [8]
HQK-1004 DM3WX0K Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
Rilapladib DMB9861 Arteriosclerosis BD40 Phase 1 [10]
Ad-OC-hsvTK/valacyclovir DM9GLHO Prostate cancer 2C82.0 Phase 1 [11]
Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy DMO8SGD Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Thymidine kinase 1 (TK1) TTP3QRF KITH_HUMAN Inhibitor [1]
Thymidine kinase 2 (Mt-TK2) TT7KNZQ KITM_HUMAN Inhibitor [1]

References

1 N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
2 Clinical pipeline report, company report or official report of Modis Therapeutics.
3 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4 Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9.
5 Company report (Takara Bio)
6 Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol. 2002 Feb;61(2):249-54.
7 Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8.
8 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
9 Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001 Sep;13(5):360-7.
10 Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1):15-22.
11 Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003 Feb 10;14(3):227-41.
12 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.